Related Experiment Video

Updated: Sep 4, 2025

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
08:56

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

11.0K

Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic

Hong Lin1, Yuxi Wang2, Pinghan Wang3

  • 1Department of Pharmacy, Sichuan Cancer Hospital & Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Molecular Cancer
|July 17, 2022
PubMed

Insights

Tumor cells resist cancer therapy, but understanding N6-methyladenosine (m6A) modifications and circular RNAs (circRNAs) offers new strategies. Their interplay impacts treatment sensitivity and overcoming cancer resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Therapeutic resistance in cancer leads to recurrence and metastasis.
  • N6-methyladenosine (m6A) is a key RNA modification influencing gene expression and cancer progression.
  • Circular RNAs (circRNAs) are emerging as critical regulators in anticancer therapy.

Purpose of the Study:

  • To review recent advances in m6A modification and circRNAs in cancer therapeutic resistance.
  • To explore the interplay between m6A and circRNAs in modulating treatment sensitivity.
  • To provide insights into potential mechanisms and future directions for overcoming cancer resistance.

Main Methods:

  • Literature review of recent studies on m6A, circRNAs, and cancer therapy.
  • Analysis of the regulatory roles and interactions of m6A and circRNAs.
  • Synthesis of findings related to therapeutic resistance mechanisms.

Main Results:

  • m6A modification and circRNAs are mutually regulated and impact cancer treatment sensitivity.
  • The interaction between m6A and circRNAs plays a significant role in modulating therapeutic resistance.
  • Understanding these interactions offers novel strategies for cancer treatment.

Conclusions:

  • m6A modification and circRNAs are crucial players in cancer therapeutic resistance.
  • Their interplay presents promising therapeutic targets for reversing resistance.
  • Further research into these mechanisms can guide the development of effective cancer therapies.
Keywords:
CancerCircular RNAInterplayN6-methyladenosineTherapeutic resistance

More Related Videos

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry08:45

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry

Published on: April 21, 2022

2.5K
Methylated RNA Immunoprecipitation Assay to Study m5C Modification in Arabidopsis08:50

Methylated RNA Immunoprecipitation Assay to Study m5C Modification in Arabidopsis

Published on: May 14, 2020

6.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.1K
Translational Regulation01:29

Translational Regulation

Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...
88
RNA Stability01:53

RNA Stability

Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
33.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K